Clorox (CLX) Common Equity (2009 - 2026)

Clorox's Common Equity history runs 18 years deep, the most recent figure standing at $92.0 million for Q1 2026.

• On a quarterly basis, Common Equity fell 51.58% year-over-year to $92.0 million in Q1 2026; TTM through Mar 2026 was $92.0 million, a 51.58% decrease from a year earlier, with the FY2025 full-year figure at $482.0 million, down 2.03% from the prior year.
• Common Equity climbed to $92.0 million in Q1 2026 per CLX's latest filing, from $35.0 million in the prior quarter.
• Across five years, Common Equity topped out at $729.0 million in Q2 2022 and bottomed at $35.0 million in Q4 2025.
• The 5-year median for Common Equity is $224.0 million (2024), against an average of $307.6 million.
• Across the five-year window, Common Equity plunged 73.59% in 2023 and surged 70.99% in 2024, its largest moves.
• Year by year, Common Equity stood at $491.0 million in 2022, then slumped by 55.6% to $218.0 million in 2023, then tumbled by 44.5% to $121.0 million in 2024, then slumped by 71.07% to $35.0 million in 2025, then soared by 162.86% to $92.0 million in 2026.
• Per Business Quant, the three latest CLX Common Equity figures stand at $92.0 million (Q1 2026), $35.0 million (Q4 2025), and $138.0 million (Q3 2025).